<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04210765</url>
  </required_header>
  <id_info>
    <org_study_id>2019.08.1.04.061</org_study_id>
    <nct_id>NCT04210765</nct_id>
  </id_info>
  <brief_title>Incremental Clomiphene Citrate Doses in Successive Cycles and FSH, LH and Steroid Hormone Levels</brief_title>
  <official_title>The Effect of Incremental Clomiphene Citrate(CC) Doses in Successive Induction Cycles on the Endogenous Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Steroid Hormone Responses to Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bagcilar Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bagcilar Training and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was planned to assess the initial and endogenous FSH, LH and steroid responses to
      incremental CC doses in successive ovulation induction cycles to treat anovulation in
      patients with unexplained infertility.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the Bagcilar Research and Training Hospital Obstetrics and Gynecology department
      outpatient clinic for infertility, the basal gonadotropin and androgen levels are routinely
      measured. In unexplained infertility couples with normal ovarian reserves the first line drug
      used for ovulation induction is CC. The starting dose is 50mg/day and the treatment is
      started within the 2nd to the 5th days of the menstrual cycle and continued for 5 days.
      Starting on the 2nd-3rd day following the last dose of the drug, the follicular growth was
      monitored with the transvaginal ultrasound and blood levels of hormones including FSH, LH,
      estradiol, progesterone, androstenedione, testosterone, and dehydroepiandrosterone sulphate
      were measured every 2-3 days. In this follow-up, if no follicular growth was observed day21
      of the cycle, the CC dose was increased to CC 100mg/day (2X1, 50mg). If follicular growth and
      ovulation is achieved with no concluding conception, the same dose of CC is used in the
      following 2-3 cycles. When a maximum number of 2 dominant follicles are obtained ovulation is
      triggered with recombinant human chorionic gonadotropin (rhCG) and timed coit or intrauterine
      insemination is conducted.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2, 2019</start_date>
  <completion_date type="Anticipated">May 25, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 20, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the endogenous blood levels of FSH, LH in successive cycles</measure>
    <time_frame>Menstrual cycle at day 3 and day 9 and the trigger day respectively (each cycle is 28 days</time_frame>
    <description>FSH (mIU/ml), LH (mIU/ml) blood levels measured with Enzyme-Linked ImmunoSorbent Assay (ELISA) tests.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in the endogenous blood levels of steroids (including Androstenedione, Progesterone, Testosterone, estradiol) in successive cycles</measure>
    <time_frame>Menstrual cycle at day 3 and day 9 and the trigger day respectively (each cycle is 28 days)</time_frame>
    <description>Blood levels of steroids: Androstenedione (ng/ml), Progesterone (ng/ml), Testosterone (ng/ml), estradiol (pg/ml) measured with ELISA tests.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>conception rate</measure>
    <time_frame>15-20 days following intrauterine insemination.</time_frame>
    <description>beta-hCG (IU/L)measured with ELISA.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Unexplained Infertility</condition>
  <condition>Ovulation Disorder</condition>
  <arm_group>
    <arm_group_label>Clomiphene citrate group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clomiphene citrate dose 50mg/day for 5 days starting on cycle day (2-4).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clomiphene citrate group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Non-responsive to ovulation induction with Clomiphene Citrate with dose:50mg/day; and treated with dose:100mg/day in the succeeding cycle for 5 days, starting on cycle day (2-4).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clomiphene Citrate</intervention_name>
    <description>Clomiphene citrate used in incremental doses in nonresponsive cases.</description>
    <arm_group_label>Clomiphene citrate group 1</arm_group_label>
    <arm_group_label>Clomiphene citrate group 2</arm_group_label>
    <other_name>CC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20-35 years of age

          -  unexplained infertility

          -  first-line treatment

          -  Normal or increased ovarian reserve

          -  lack of ovulatory response to CC 50mg for 5 days

        Exclusion Criteria:

          -  Male factor

          -  Tubal Factor

          -  Severe endometriosis

          -  Previous ovarian surgery
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Women with unexplained infertility</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evrim E Kovalak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bagcilar Training and Research Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Evrim E Kovalak, MD</last_name>
    <phone>+905324628989</phone>
    <email>evrimebru@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Şefik E Özyürek, MD</last_name>
    <phone>+905309322345</phone>
    <email>eozyurek@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bagcilar Teaching and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <state>Bagcilar</state>
        <zip>34200</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evrim E Kovalak, MD</last_name>
      <phone>+905324628989</phone>
      <email>evrimebru@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Şefik E Özyürek, MD</last_name>
      <phone>+905309322345</phone>
      <email>eozyurek@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Ozyurek ES, Yoldemir T, Artar G. Androstenedione response to recombinant human FSH is the most valid predictor of the number of selected follicles in polycystic ovarian syndrome: (a case-control study). J Ovarian Res. 2017 May 12;10(1):34. doi: 10.1186/s13048-017-0330-7.</citation>
    <PMID>28494798</PMID>
  </reference>
  <reference>
    <citation>Hager M, Hörath S, Frigo P, Koch M, Marculescu R, Ott J. Changes in serum markers of patients with PCOS during consecutive clomiphene stimulation cycles: a retrospective study. J Ovarian Res. 2019 Oct 4;12(1):91. doi: 10.1186/s13048-019-0564-7.</citation>
    <PMID>31585548</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 13, 2019</study_first_submitted>
  <study_first_submitted_qc>December 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2019</study_first_posted>
  <last_update_submitted>December 24, 2019</last_update_submitted>
  <last_update_submitted_qc>December 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>infertility</keyword>
  <keyword>unexplained infertility</keyword>
  <keyword>ovulation induction</keyword>
  <keyword>clomiphene citrate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Enclomiphene</mesh_term>
    <mesh_term>Zuclomiphene</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://dremrahkovalak.com/wp-content/uploads/2019/12/registration.pdf</doc_url>
      <doc_comment>unfinished</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

